New concepts and tools in imaging for the study of neurodegenerative disease

Journal of Neural Transmission, Supplement

Volumn , Issue 65, 2003, Pages 157-166

  Stoessl, A J ^a   Lee, C S ^a   De La Fuente Fernandez, R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN RECEPTOR; CARBON 11; DOPAMINE; LEVODOPA; NEUROTRANSMITTER; RACLOPRIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARBON; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT;

CONFERENCE PAPER; DEGENERATIVE DISEASE; HUMAN; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPSE; CELL TRANSPLANTATION; DIAGNOSTIC IMAGING; DISEASE COURSE; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SENSORY RECEPTOR;

CARBON RADIOISOTOPES; CELL TRANSPLANTATION; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROTRANSMITTER AGENTS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, SENSORY;

EID: 0142010010     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0643-3_9     Document Type: Conference Paper

References (64)

1. Antonini A, Leenders KL, Vontobel P et al (1997a) Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120: 2187-2195
2. 11C]raclopride. Mov Disord 12: 33-38
3. Banati RB, Cagnin A, Myers R et al (1999) In vivo detection of activated microglia by [11C]PK11195-PET indicates involvement of the globus pallidum in idiopathic Parkinson's disease. Parkinsonism Rel Disord 5: S56-S57
4. Bhaumik S, Gambhir SS (2002) Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 99: 377-382
5. Breier A, Su T-P, Saunders R et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574
6. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28: 547-555
7. Brooks DJ, Salmon EP, Mathias CJ et al (1990a) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 113: 1539-1552
8. 11C-raclopride and positron emission tomography. Ann Neurol 31: 184-192
9. 18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 55: 877-879
10. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 57: 278-284
11. Calne DB (1994) Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44: 4-10
12. de la Fuente-Fernandez R, Lim AS, Sossi V et al (2001a) Apomorphine-induced changes in synaptic dopamine levels: PET evidence for pre-synaptic inhibition. J Cereb Blood Flow Metab 21: 1151-1159
13. de la Fuente-Fernandez R, Lu JQ, Sossi V et al (2001b) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49: 298-303
14. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001c) Expectation and dopamine release: mechanism of the placebo effect in parkinson's disease. Science 293: 1164-1166
15. de la Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136: 359-363
16. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45: 1995-2004
17. Feigin A, Fukuda M, Dhawan V et al (2001) Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57: 2083-2088
18. Fernandez HH, Friedman JH, Fischman AJ, Noto RB, Lannon MC (2001) Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Med Sci Monit 7: 1339-1343
19. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48: 1077-1082
20. Freeman TB, Olanow CW, Hauser RA et al (1995) Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 38: 379-388
21. Frey KA, Koeppe RA, Kilbourn MR et al (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40: 873-884
22. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34: 423-431
23. Fukuda M, Mentis M, Ghilardi MF et al (2001) Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol 49: 155-164
24. Gambhir SS, Bauer E, Black ME et al (2000) A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 97: 2785-2790
25. Garnett ES, Firnau G, Nahmias C (1983a) Dopamine visualized in the basal ganglia of living man. Nature 305: 137-138
26. Garnett S, Firnau G, Nahmias C, Chirakal R (1983b) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280: 169-171
27. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 19: 487-492
28. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naïve Parkinson's disease: implications for the symptomatic threshold. Neurology 48: 1578-1583
29. Ishikawa T, Dhawan V, Kazumata K et al (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/ PET. J Nucl Med 37: 1760-1765
30. 18F] Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med 42: 96-105
31. Jenkins IH, Fernandez W, Playford ED et al (1992) Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32: 749-757
32. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293
33. Kishore A, de la Fuente-Fernandez R, Snow BJ, Schulzer M, Mak E, Huser J, Stoessl AJ, Calne DB (1997) Levodopa-induced dyskinesias in idiopathic parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors. Neurology 48[Suppl 2]: A327
34. Koepp MJ, Gunn RN, Lawrence AD et al (1998) Evidence for striatal dopamine release during a video game. Nature 393: 266-268
35. Kordower JH, Freeman TB, Snow BJ et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332: 1118-1124
36. Lee CS, Schulzer M, Mak EK et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117: 501-507
37. Lee CS, Samii A, Sossi V et al (2000) In vivo PET evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47: 493-503
38. 11C-DTBZ PET evidence for the "event" hypothesis. Neurology 56[Suppl 3]: A73-A74
39. 123I]beta-CIT/ SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46: 231-237
40. Marek K, Seibyl J, Shoulson I et al (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653-1661
41. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291
42. Nakamura T, Dhawan V, Chaly T et al (2001) Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 50: 181-187
43. 18F]-Dopa PET imaging in early stage, non-parkin juvenile Parkinsonism. Mov Disord 17: 789-794
44. Pate BD, Kawamata T, Yamada T et al (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331-338
45. Piccini P, Brooks DJ, Bjorklund A et al (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2: 1137-1140
46. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ (1992) Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 32: 151-161
47. 18F]beta-CFT, is reduced in early Parkinson's disease. Synapse 31: 119-124
48. Samii A, Markopoulou K, Wszolek ZK et al (1999) PET studies of parkinsonism associated with mutation in the α-synuclein gene. Neurology 53: 2097-2102
49. 15O PET study. Brain 120: 1301-1313
50. 3H raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96-97
51. Shi N, Boado RJ, Pardride WM (2000) Antisense imaging of gene expression in the brain in vivo. Proc Natl Acad Sci USA 97: 14709-14714
52. Shinotoh H, Inoue O, Hirayama K et al (1993) Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56: 467-472
53. Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35
54. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330
55. Strafella AP, Paus T, Barrett J, Dagher A (2001) Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 21: RC157
56. Tavitian B, Terrazzino S, Kuhnast B et al (1998) In vivo imaging of oligonucleotide with positron emission tomography. Nat Med 4: 467-471
57. 11C]raclopride displacement and PET. Neurology 46: 1430-1436
58. Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49: 717-723
59. Vanderborght T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577-583
60. 11C]raclopride in the human brain. Synapse 16: 255-262
61. Wenning G, Odin P, Morrish P et al (1997) Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42: 95-107
62. Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl AJ, Watts RL, Brooks DJ (2002) The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 58[Suppl 3]: A82-83
63. Wilson JM, Kish SJ (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16: 3507-3510
64. Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KE, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR (2001) Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 16: 838-848